Physician profile
Gilberto C Torres
NPI 1982677654
$5,386.72
in general payments reported to CMS, 2019-2025
18 companies · $957 in 2025
The $957 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $1,317 · 2023: $1,609 · 2024: $715 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.60 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,105.86 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $628.46 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $587.49 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $510.31 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $505.77 | 2021-2024 | Spravato, Invega Sustenna |
| Almatica Pharma LLC | $407.30 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $372.12 | 2021-2024 | Trintellix |
| Alkermes, INC. | $340.11 | 2022-2025 | Aristada, Lybalvi |
| Indivior INC. | $300.20 | 2021-2024 | Perseris |
| Lundbeck LLC | $230.39 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $95.09 | 2022-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $93.87 | 2024 | Auvelity |
| Corium, LLC | $68.49 | 2022 | |
| Sunovion Pharmaceuticals INC. | $44.00 | 2021 | |
| Supernus Pharmaceuticals, INC. | $33.87 | 2024-2025 | Qelbree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.20 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $23.42 | 2025 | Quviviq |
| Sun Pharmaceutical Industries INC. | $15.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.